News for Ultragenyx Pharmaceutical Inc. (0LIF.L)

Ultragenyx Pharmaceutical Inc. (RARE) showcases promising growth potential with substantial upside opportunities according to analysts. Experts forecast

NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and co

Summary Ultragenyx Pharmaceutical Inc (RARE), a biopharmaceutical company dedicated to developing therapies for rare and ultra-rare diseases, announced on May 2

NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and com

**media[632238]**

**media[626257]**

On May 9, 2025, Morgan Stanley announced an updated analyst report concerning Ultragenyx Pharmaceutical, with the ticker symbol (RARE). The report was issued by

**media[618170]**

Citi analysts have highlighted that Ultragenyx (RARE) shares have returned to valuations that reflect a four-fold multiple of the company's sales guidance for t

Revenue: $139 million in Q1 2025, representing 28% growth over Q1 2024.Crysvita Revenue: $103 million, with 25% growth over 2024; $41 million from North Americ

May 06, 2025 / 09:00PM GMTOperator Good afternoon, and welcome to the Ultragenyx first-quarter 2025 financial results conference call. (Operator Instructions) N

Ultragenyx Pharmaceutical Inc. (RARE) sees substantial growth in Q1 2025, with a 28% revenue increase to $139 million. Crysvita's strong performance, es

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ETCompany ParticipantsJoshua Higa - Vice President,...

First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total re

Ultragenyx (RARE) announced its first-quarter revenue of $139.29 million, falling short of the anticipated $144.46 million. As of March 31, the company held $56

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant reduction in its holdings of Ultragenyx Pharmaceutical Inc. The firm decreased its

Ultragenyx Pharmaceutical (RARE) to host its Q1 2025 earnings call on May 6, 2025. Conference call scheduled for 5:00 p.m. ET will cover financial resul

NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE), a biopharmaceutical company focused on the development and commerci

**media[611033]**